Preclinical and clinical evidence support the protective effect of crocin on different pathologic pathways involved in central serous chorioretinopathy (CSCR). They involve inflammation, oxidative stress, mineralocorticoid pathway, and also stress-related injuries. It also showed that crocin has a protective effect on the retinal pigmented epithelium (RPE) layer. Based on the mentioned evidence the study designed to evaluate the efficacy and safety of 2-month crocin supplementation (15 mg/d) in 40 patients with CSCR in a randomized controlled blinded clinical trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Shiraz University of Medical Sciences
Shiraz, Fars, Iran
RECRUITINGBest-corrected visual acuity (BCVA)
Time frame: 8 weeks
Foveal thickness (μm)
measured by OCT imaging
Time frame: 8 weeks
Subretinal fluid height (μm)
measured by OCT imaging
Time frame: 8 weeks
Subfoveal choroidal thickness (μm)
measured by OCT imaging
Time frame: 8 weeks
Number of participants need to laser therapy
based on clinical criteria
Time frame: 8 weeks
Total number of reported adverse events
based on patients reported adverse events
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.